Terumo Q4 2025 Earnings Report

Terumo EPS Results

• Actual EPS: $0.08
• Consensus EPS: $0.15
• Beat/Miss: Missed by -$0.07
• One Year Ago EPS: N/A

Terumo Revenue Results

• Actual Revenue: $1.79 billion
• Expected Revenue: $1.79 billion
• Beat/Miss: Missed by -$7.40 million
• YoY Revenue Growth: N/A

Terumo Announcement Details

• Quarter: Q4 2025
• Date: 5/14/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Terumo (OTCMKTS:TRUMY) Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags. Through its Terumo BCT subsidiary, the company also provides apheresis, blood component management and cell therapy technologies used by blood banks, transfusion services and cell-therapy developers. Terumo’s portfolio emphasizes single-use medical devices and clinically oriented systems designed to improve procedural outcomes and patient safety.

Founded in the early 20th century and headquartered in Tokyo, Terumo has grown into a multinational supplier with operations and sales networks across Asia, the Americas and Europe. The company distributes products globally through a combination of regional subsidiaries, direct sales teams and distribution partners, serving hospitals, specialty clinics and blood centers. As a publicly listed Japanese corporation, Terumo also maintains an American depositary receipt (ADR) listing that enables trading on overseas markets.